Adding pembrolizumab (Keytruda) to first-line chemotherapy improves response and survival rates among patients with previously-untreated advanced PD-L1-positive non-small cell lung cancer.
Adding pembrolizumab (Keytruda) to first-line chemotherapy improves response and survival rates among patients with previously-untreated advanced PD-L1-positive non-small cell lung cancer (NSCLC), according to findings from the phase III KEYNOTE-024 trial. The findings were presented at the European Society for Medical Oncology (ESMO) Congress, held October 7-11, 2016, in Copenhagen, Denmark, and were published in TheNew England Journal of Medicine.
The findings set the stage for pembrolizumab’s use as a first-line treatment for this patient population. It is currently approved by the US Food and Drug Administration as a second-line therapy.
“In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy,” reported lead study author Martin Reck, MD, PhD, chief oncology physician at the German Center of Lung Research in Grosshansdorf, Germany, and coauthors.
Between 27% and 30% of patients with NSCLC harbor tumors expressing high levels of the programmed cell death ligand 1 (PD-L1), Dr. Reck noted. Pembrolizumab is a humanized antibody immune checkpoint blockade immunotherapy.
A total of 305 patients in 16 countries were randomly assigned (1:1) to receive either a platinum-based chemotherapy or pembrolizumab at the fixed dose of 200 mg every 3 weeks. Patients in the pembrolizumab group had a median progression-free survival (PFS) of 10.3 months, compared to 6.0 months for the chemotherapy group (hazard ratio [HR] for death, 0.50; 95% CI, 0.37-0.68, P < .001).
“The estimated rate of overall survival [OS] at 6 months was 80.2% in the pembrolizumab group versus 72.4% in the chemotherapy group” (HR, 0.60; 95% CI, 0.41-0.89; P = .005),” the coauthors reported.
Response rates were higher among patients administered pembrolizumab than chemotherapy (44.8% vs 27.8%), and median duration of response was longer (not reached vs 6.3 months).
Treatment-related adverse events occurred in 73.4% of pembrolizumab-group patients (grade 3+: 26.6%), and 90% of patients receiving chemotherapy (grade 3+: 53.3%).
The findings “may establish a new standard of care for previously untreated patients with NSCLC and a PD-L1 tumor proportion score of 50% or greater,” noted authors of an editorial by Bruce E. Johnson, MD, published alongside the study.
KEYNOTE-024 was funded by Merck.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
Advancing Thoracic Surgery With Robotics and Video-Assisted Strategies
June 13th 2024"Anything that you can do to leverage technology to minimize the variability in surgery eliminates the skill gap so that novice surgeons may become as technically gifted as the intermediate surgeon or the master surgeon."